Spectrum Pharmaceutecals Inc (SPPI)

[Ville7]

"Hope you are right regarding the poziotinib Korean BC study but I'm a little skeptical still."

You don't have to. I can't remember that a SPPI drug ever reached this high category at a congress. The highest i know was a poster discussion, which is not bad. Proffered paper is really data of high significance. And -in addition- it was accepted as a late breaking abstract.

Here are the categories:

Presidential Symposium – Oral presentations by authors of the very best abstracts containing cutting-edge and significant clinical practice-changing studies, followed by expert discussion and perspectives.

Proffered Paper – Oral presentations by authors presenting original data of superior quality, followed by expert discussion and perspectives.

Poster Discussion – Presentation and analysis by an invited speaker highlighting important findings within a disease type or about a common theme plus interactive audience discussion.

Poster – Display sessions for review, discussion and questions. Rotated by category, posters will be displayed for one day of the Congress and the presenting authors must be available for Q&A for one hour to represent their work.

Late-breaking abstracts may be submitted for high quality, new research findings with implications for clinical practice or understanding of disease processes[/u].

I therefor think that they reached the 30% ORR threshold it needs for a later line single agent drug to get approved by the agencies

The comittee could even change the proffered paper status shortly before the meeting if they believe the data could be practice changing. So did they with cabozantinib last year which first was a proffered paper.